Table 1.
The Treatment Protocol for Patients With Thalassemia Major and Hepatitis C.
| Genotype | Characteristics of patients | Direct acting antivirals | Duration (weeks) | Number of patients in the present studya |
|---|---|---|---|---|
| GT1 | Treatment naïve and fibroscan ≤8 kPa | Sofosbuvir + ledipasvir | 12 | 5 |
| Treatment naïve/experienced and fibroscan >8 kPa | Sofosbuvir + ledipasvir + ribavirin or sofosbuvir + ledipasvir | 12 24 |
12 | |
| GT3 | Treatment naïve and fibroscan ≤8 kPa | Sofosbuvir + daclatasvir | 12 | 1 |
| Treatment naïve and fibroscan > 8 kPa or treatment experienced | Sofosbuvir + daclatasvir + ribavirin or sofosbuvir + daclatasvir | 12 24 |
10 |
a
The sum of patients is 28 as one patient had undetectable genotype and was treated with sofosbuvir/daclatasvir based therapy. Fibroscan score of 8 kPa was considered as a cut-off for presence of significant fibrosis and these patients were treated as compensated cirrhosis.